Reaction
Intestinal Ulcer reporting signals
As of the last recalculation, Intestinal Ulcer appears in 1,561 FAERS reports alongside 17 co-occurring drug terms. The strongest observed disproportionality signal is INFLIXIMAB-DYYB (PRR 15.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Infliximab-Dyyb | 34 | 15.8 | 15.9 |
| Vedolizumab | 96 | 15.8 | 15.8 |
| Encorafenib | 9 | 12.2 | 12.2 |
| Azathioprine | 74 | 11.7 | 11.7 |
| Erlotinib | 8 | 11.1 | 11.1 |
| Mesalamine | 44 | 10.7 | 10.7 |
| Ganciclovir Sodium | 8 | 10.1 | 10.1 |
| Erlotinib Hydrochloride | 9 | 9.6 | 9.6 |
| Infliximab | 134 | 8.9 | 8.9 |
| Instalax Polyethylene Glycol 3350 | 8 | 8.6 | 8.6 |
| Adalimumab | 358 | 8.5 | 8.5 |
| Polyethylene Glycol 400 | 8 | 8.4 | 8.5 |
| Iron Sucrose | 6 | 8.4 | 8.4 |
| Azacitidine For | 11 | 8.1 | 8.1 |
| Teduglutide | 7 | 7.0 | 7.0 |
| Ustekinumab | 50 | 6.7 | 6.7 |
| Azacitidine | 12 | 5.4 | 5.4 |